Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Amondys 45 (casimersen)
- Voxzogo (vosoritide)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food/lifestyle interactions
vosoritide food/lifestyle
Applies to: Voxzogo (vosoritide)
MONITOR: Vosoritide may cause transient decreases in blood pressure. In clinical trials, 13% of patients treated with vosoritide experienced a transient decrease in blood pressure compared to 5% of patients on placebo. The median time to onset from injection was 31 (18 to 120) minutes with resolution within 31 (5 to 90) minutes. Two out of 60 (3%) vosoritide-treated patients each had one symptomatic episode of decreased blood pressure with vomiting and/or dizziness compared to 0 of 61 (0%) patients on placebo.
MANAGEMENT: To reduce the risk of low blood pressure and its associated signs and symptoms, patients should have adequate food intake before vosoritide administration and should drink approximately 240 to 300 mL of fluid within the hour prior to vosoritide administration. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience fatigue, nausea, dizziness, or lightheadedness.
References (1)
- (2022) "Product Information. Voxzogo (vosoritide)." BioMarin Pharmaceutical Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Vyondys 53
Vyondys 53 is used for Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Exondys 51
Exondys 51 is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a ...
Elevidys
Elevidys is a gene therapy for Duchenne muscular dystrophy, that is given as a one-time infusion ...
Duvyzat
Duvyzat (givinostat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Agamree
Agamree (vamorolone) is an FDA-approved treatment for Duchenne muscular dystrophy (DMD) to improve ...
Emflaza
Emflaza (deflazacort) is a corticosteroid medication used to treat a rare genetic disorder called ...
Viltepso
Viltepso (viltolarsen) is used for the treatment of Duchenne muscular dystrophy (DMD) treatable ...
Golodirsen
Golodirsen is used to treat Duchenne muscular dystrophy (DMD) in children and young adults with a ...
Givinostat
Givinostat (Duvyzat) is used to treat Duchenne muscular dystrophy (DMD) to delay symptoms and ...
Eteplirsen
Eteplirsen is used for Duchenne Muscular Dystrophy (DMD) in children and young adults with a gene ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.